1.Current status and progress on non-surgical treatment of patients with primary liver cancer
Siyao CHE ; Longguang HE ; Qinshou CHEN ; Simin HUANG
Chinese Journal of Hepatobiliary Surgery 2016;22(6):428-432
Primary liver cancer ( PLC) , the most com-mon malignant carcinoma in the world , greatly impairs the hu-man health .Various treatments for PLC have been practiced but the therapeutic effects are still unsatisfied .Nowadays, interven-tional therapy , chemotherapy , radiotherapy , molecular targeted therapy and radiofrequency ablation are playing a key role in hepatocellular carcinoma treatment .In near future , more ad-vancements on comprehensive therapy for PLC are being expec-ted.This review aimed to describe the recent scenario and cur-rent advancement on non-surgical treatment for hepatocellular carcinoma .
2.Combined superselective transcatheter arterial chemoembolization and selective intraportal venous embolization for the treatment of inoperable advanced primary liver cancer
Meirong LI ; Guanrui YE ; Huadong CHEN ; Yunfu LI ; Sibo PAN ; Yanjin HUANG ; Qinshou CHEN ; Yongren LIANG
Chinese Journal of General Surgery 1993;0(01):-
Objective To evaluate superselective transcatheter arterial chemoembolization ( TACE) plus selective portal vein embolization (SPVE) and large dose of lipiodol on advanced primary liver carcinoma (PHC).Methods Two hundred and three cases of advanced PHC were randomly divided into group treated with ordinary TACE, and that with TACE +SPVE. Results The response rate (CR+PR) was 38% in TACE group and 59% in TACE+SPVE group (P
Result Analysis
Print
Save
E-mail